Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs

Murphy and colleagues report a cost-effectiveness analysis of sublingual buprenorphine with naloxone versus extended-release naltrexone to treat opioid use disorder. The editorialists believe the analysis is an eloquent demonstration of how cost-effectiveness analysis forces us to be explicit about the factors that influence our decisions.

from A via a.sfakia on Inoreader https://ift.tt/2Llbuvc